NCT04306926 - A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

October 31, 2022

Study Completion Date

May 30, 2023

Conditions

Advanced Oligometastatic Non-small Cell Lung Cancer

Interventions

DRUG

TQB2450

TQB2450 1200mg administered IV on Day 1 of each 21-day cycle.

RADIATION

SBRT

Give according to the location of the lesion and clinical condition.

Trial Locations (4)

Beijing Cancer Hospital, Beijing

Peking University Third Hospital, Beijing

Huashan Hospital Fudan University, Shanghai

Tianjin Medical University Cancer institute and Hospital, Tianjin